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Note
Making Your Robotic Surgery Systems General
Purpose: A Possible Preventive Measure for
Induced and Contributory Infringement Liability
Arising in Medical Procedures
Mengmeng Du*
Not only is robotic surgery among the most important
advancements in the medical device industry in the twentieth
century, it is also one of the most important implementations of
robotics techniques.1 Robotic surgery systems have enormous
advantages over traditional surgical technologies.2 Hospitals
worldwide have adopted robotic surgery in the treatment of a
wide range of conditions.3 Innovation in robotic surgery pushes
society forward by providing better health care and extending
human lifespan.4 Thus, laws in this country should preserve
rather than diminish incentives for innovation in this field in
order to benefit the public. However, under the current patent
system in the United States, secondary liabilities arising from
© 2022 Mengmeng Du
* J.D., 2022, University of Minnesota Law School; M.S. Electrical and
Electronics Engineering, 2016, Georgia Institute of Technology; B.E.
Automation, 2014, Beijing Institute of Technology. I thank Professor Thomas F.
Cotter for guiding me through the note-writing process; Ian Sannes for his
comments on previous versions of this Note; the editorial staff at Minnesota
Journal of Law, Science & Technology for all of their feedback; and my family
and friends who have supported me through law school. Any errors that remain
are mine alone.
1. See generally Jeff Glorfeld, 10 Most Exciting Developments with Robots,
COSMOS (Jan. 16, 2019), https://cosmosmagazine.com/technology/the-10-mostexciting-robotics-developments-of-the-past-12-months/ (detailing interesting
and important robotic advancements, including robotic surgery advancements).
2. See infra Part I (discussing the advantages that robotic surgery systems
have over traditional surgical techniques); Robotic Surgery, MAYO CLINIC
[hereinafter Robotic Surgery], https://www.mayoclinic.org/tests-procedures
/robotic-surgery/about/pac-20394974 (last visited Mar. 14, 2022) (discussing the
advantages and risks of robotic surgery).
3. See Robotic Surgery, supra note 2.
4. See infra Part I.A. (discussing the development of robotic surgical
technologies).
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indirect infringement erode the innovation incentives for robotic
surgery system developers in various ways, including increasing
R&D costs and incurring expenses for responding to lawsuits.5
This Note utilizes the general-purpose characteristic of
future robotic surgery systems to develop a new strategy for
supplier companies to shield themselves from indirect
infringement accusations. This Note unfolds in the following
manner. Part I introduces the relevant background information
of robotic surgery systems, including the history and the future
trend of robotic surgery technology and the government’s
regulation scheme of robotic surgery systems and devices. Part I
also provides an overview of indirect infringement lawsuits
brought against robotic surgery system suppliers and the IP
strategies suppliers have pursued in response to the situation to
demonstrate the need for an alternative legal strategy. Part II
analyzes how the general-purpose characteristic of a robotic
surgery system provides a valid defense to indirect infringement
and how making the robotic surgery system more generalpurpose aligns with companies’ commercial goals. This Note
concludes that making a robotic surgery system more generalpurpose provides a defense to secondary liabilities resulting
from indirect infringement that is both legally viable and
commercially desirable.
I. BACKGROUND
Today, many surgical devices carry some computer-assisted
features. Examples familiar to lay people include imaging
technologies, such as computerized tomography (CT) scans,6
magnetic resonance imaging (MRIs),7 X-rays,8 and procedures
using surgical navigation instruments such as endoscopy9 and
cardiac catheterization.10 Robotic surgery systems, robotically-

5. See infra Part I.C. (detailing some of the issues with the United States
patent system as it relates to robotic surgery technologies).
6. CT Scan, MAYO CLINIC, https://www.mayoclinic.org/tests-procedures/ct
-scan/about/pac-20393675 (last visited Mar. 14, 2022).
7. MRI, MAYO CLINIC, https://www.mayoclinic.org/tests-procedures/mri
/about/pac-20384768 (last visited Mar. 14, 2022).
8. X-ray, MAYO CLINIC, https://www.mayoclinic.org/tests-procedures/xray/about/pac-20395303 (last visited Mar. 14, 2022).
9. Endoscopy, MAYO CLINIC, https://www.mayoclinic.org/tests-procedures
/endoscopy/multimedia/endoscopy/img-20007299 (last visited Mar. 14, 2022).
10. Cardiac Catheterization, MAYO CLINIC, https://www.mayoclinic.org/

2022] MAKING ROBOTIC SURGERY GENERAL PURPOSE 595

assisted surgical devices, and surgical robots belong to the
category of computer-assisted surgical systems.11 Surgical
robots generally refer to mechanical devices and systems that
mainly comprise mechanical arms, consoles, and a viewing
apparatus, and are computer-centric and human-controlled.12
Compared to traditional surgery techniques, robotic surgery
technology allows physicians to perform a variety of complex
procedures with better precision, flexibility, and most
importantly, a higher level of control.13 These numerous
advantages make robotic surgery technology highly desirable in
operating rooms, especially where minimally invasive surgical
procedures14 are performed.15 Experts have also envisioned
using robotic surgical systems in telesurgery or remote surgery
in the near future.16

tests-procedures/cardiac-catheterization/about/pac-20384695 (last visited Mar.
14, 2022).
11. See Computer-Assisted Surgical Systems, U.S. FOOD & DRUG ADMIN.
[hereinafter Computer-Assisted Surgical Systems], https://www.fda.gov/medical
-devices/surgery-devices/computer-assisted-surgical-systems (last visited Mar.
14, 2022) (defining computer-assisted surgical systems, which includes robotic
surgery systems and devices).
12. Robotic Surgery, supra note 2.
13. Robotic Surgery, supra note 2; G. P. Moustris et. al., Evolution of
Autonomous and Semi-Autonomous Robotic Surgical Systems: A Review of the
Literature, 7 INT’L J. MED. ROBOTICS & COMPUTER ASSISTED SURGERY 375, 375
(2011) (suggesting that autonomous control of robotic surgical systems offer
advantages such as less tissue-damage to the patient and more intelligent
maneuvers to assist the surgeon).
14. Minimally invasive surgery refers to surgical procedures that require a
smaller incision on the human body compared to traditional open surgery to
complete the procedure. Minimally Invasive Surgery, MAYO CLINIC, https://
www.mayoclinic.org/tests-procedures/minimally-invasive-surgery/about/pac20384771 (last visited Mar. 14, 2022). This technology emerged in the 1980s
and is becoming more and more preferred by medical practitioners today. Id.
15. Robotic surgery’s high precision and better control help further
minimize tissue damage and thus is widely implemented in minimally invasive
procedures. See Manjunath Siddaiah-Subramanya et al., A New Era of
Minimally Invasive Surgery: Progress and Development of Major Technical
Innovations in General Surgery Over the Last Decade, 3 SURGERY J. 163 (2017)
(discussing the application of robotic surgery to minimally invasive surgeries).
16. Telesurgery and remote surgery use wireless networking and robotic
technology to allow surgeons to operate on patients who are far away. Paul J.
Choi et al., Telesurgery: Past, Present, and Future, CUREUS, May 2018, at 1, 1;
see also Kenoki Ohuchida & Makoto Hashizume, Overview of Robotic Surgery,
in ROBOTIC SURGERY 1, 6 (Go Watanabe ed., 2014) (“[I]n the future, robotic
system[s] will make it possible to perform surgical procedure[s] in the
battlefield or . . . outer space without sending surgeons.”).
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A. THE DEVELOPMENT OF ROBOTIC SURGICAL TECHNOLOGY
Although conceived by medical practitioners as far back as
1967, it took nearly thirty years for researchers to complete the
first fully functional multipurpose surgical robot.17 As with other
computer-controlled technologies, the development in robotic
surgery technology relies heavily on advancements in control
engineering, artificial intelligence, and robotics.18 It started late
and developed slowly in the first thirty years.19 In 1961, the first
installed industrial robot was patented.20 Fuzzy logic, which has
been widely applied in machine control and the foundation for
artificial intelligence, came into existence in 1965.21 The first
multitasking, parallel programming language for robot control
appeared between 1982 and 1986.22 Finally, these and other
leaps in mechanical engineering, electrical engineering,
material science, and computer science together prepared the
industry, and the world saw its first surgical robot––the
Arthrobot—created and used for the first time in 1985.23
In the following thirty years, the industry saw a boom in
robotic surgery technology. Computer Motion, Inc. developed one
of the earliest commercial surgery robots, Automated
Endoscopic System for Optimal Positioning (AESOP) for intraabdominal surgeries, which FDA approved in 1994.24 Four years
later, Computer Motion introduced the ZEUS Robotic Surgical

17. Evalyn I. George et al., Origins of Robotic Surgery: From Skepticism to
Standard of Care, 22 J. SOC’Y LAPAROENDOSCOPIC SURGEONS, Oct.–Dec. 2018,
at 1, 1.
18. See id. at 7–12 (discussing the advancements in robotic surgery
technology and the influence of better control systems, haptic feedback
programming, and improved robotic techniques).
19. Id. at 1.
20. See U.S. Patent No. 2,988,237 (issued June 13, 1961) (describing the
“programmed article transfer” device and its use).
21. Lotfi A. Zadeh, Fuzzy Sets, 8 INFO. & CONTROL 338, 338 (1965).
22. See Stevo Bozinovski, Parallel Programing for Mobile Robot Control:
Agent-Based Approach, in 14TH INTERNATIONAL CONFERENCE ON DISTRIBUTED
COMPUTING SYSTEMS, 202, 202–03 (1994) (“From 1982 to 1986 we carried out
the ADRIEL (ADaptive Robot of the Institute of ELectronics) project: to design
and construct mobile robots for educational purposes.”).
23. Olga Lechky, World’s First Surgical Robot in B.C., 21 MED. POST 92
(1985).
24. Alberto Mendivil et al., Emergence of Robotic Assisted Surgery in
Gynecologic Oncology: American Perspective, 114 GYNECOLOGIC ONCOLOGY
S24, S25 (2009); see Robotic Surgery, NASA (2000), https://spinoff.nasa
.gov/spinoff2000/hm1.htm (providing further details about AESOP).
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System,25 which was exclusively tailored for treatment in
minimally invasive microsurgery procedures such as beating
heart surgery and endoscopic coronary artery bypass grafting
that typically employ an endoscopy and tissue retractor.26
After Intuitive Surgical, Inc.27 acquired Computer Motion in
2003,28 Intuitive Surgical’s main product, the da Vinci series,29
replaced ZEUS and has dominated the market of robotic surgery
system ever since.30 Since launching the first da Vinci surgical
system in 2000, Intuitive Surgical has marketed altogether at
least four generations of surgical robot––the da Vinci Standard
System, the da Vinci S System, the da Vinci Si Surgical System,
and the da Vinci SP Surgical System, respectively, in the past
twenty years.31 Built based on the technologies developed in
ZEUS, different generation da Vinci systems share the main
components—a surgical console, surgical cart, and vision cart.32
Earlier versions of da Vinci systems also resemble ZEUS in
functionality aspects––they are specialized surgical robots
developed mainly for particular uses within certain cavities of
the human body.33 Major improvements on generations of da
Vinci systems include expansion of the types and sizes of
available wristed instruments attachable to the surgical console
for operating on patients, the imaging techniques—including
equipment of high-definition video to assist vision of surgeons—
25. Mendivil et al., supra note 24, at S25.
26. Jacques Marescaux & Francesco Rubino, The ZEUS Robotic System:
Experimental and Clinical Applications, 83 SURGICAL CLINICS NORTH AM.
1305, 1306–11 (2003).
27. INTUITIVE SURGICAL, https://www.intuitive.com/en-us (last visited
Mar. 14, 2022). Founded in 1995, Intuitive Surgical has aimed at developing a
“reliable, intuitive, surgical device that would deliver the benefits of minimally
invasive surgery to the patient while preserving the benefits of open surgery for
the operator.” M.E. Hagen & M.J. Curet, The da Vinci Surgical Systems, in
ROBOTIC SURGERY 9, 10 (Go Watanabe ed., 2014).
28. Intuitive Surgical and Computer Motion Close Merger, INTUITIVE
SURGICAL (June 30, 2003), https://isrg.intuitive.com/node/7401/pdf.
29. See Intuitive History, INTUITIVE SURGICAL [hereinafter Intuitive
History],
https://www.intuitive.com/en-us/about-us/company/history
(last
visited Nov. 28, 2020) (discussing the history of Intuitive and the da Vinci
series).
30. In fact, the da Vinci Surgical System is still “the only commercially
available master-slave robotic system.” See Ohuchida & Hashizume, supra note
16, at 2.
31. Intuitive History, supra note 29.
32. Hagen & Curet, supra note 27, at 11.
33. Id.
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and improvement to user interfaces—such as the adding of a
second console for two surgeons to collaborate in a surgery or
training.34
The market for robotic surgery systems continues to grow.35
Though Intuitive Surgical’s da Vinci remains currently the only
commercially available product as of 2020,36 the bright future of
minimally invasive surgery and telesurgery has incentivized
more medical device companies to develop their own robotic
surgery systems. Examples include the VELYS Robotic-Assisted
Solution, created by Johnson & Johnson,37 and the Hugo RAS
System from Medtronic.38
The room for improvement remains large for robotic surgery
systems besides the endless pursuit of better control and higher
precision. Current problems of robotic surgical systems center
on the high purchase cost of robotic surgery systems.39 Common

34. Id.
35. Compare Medical Robotics and Computer-Assisted Surgery: The
Global Market, BCC RSCH. (June 2014), https://www.bccresearch
.com/market-research/healthcare/medical-robotics-mrcas-market-hlc036f
.html (“The global market for medical robotics and computer-assisted
surgical . . . equipment was worth nearly $2.7 billion in 2013. The market is
projected to approach $3.3 billion in 2014 and $4.6 billion by 2019 . . . .”),
with Medical Robotics and Computer-Assisted Surgery: The Global Market,
BCC RSCH. (July 2021), https://www.bccresearch.com/market-research
/healthcare/medical-robotics-mrcas-market.html (“The global market for
surgical robotics and computer-assisted surgery should grow from $6.1
billion in 2020 to $11.6 billion by 2025 with a compound annual growth
rate . . . of 13.5% for the period of 2020-2025.”).
36. Ohuchida & Hashizume, supra note 16, at 2.
37. The FDA gave DePuy Synthes 510(k) FDA clearance on January 19,
2021, for VELYS Robotic-Assisted Solution designed for use in a knee
replacement surgery system. DePuy Synthes Receives 510(k) FDA Clearance for
VELYS Robotic-Assisted Solution Designed for Use with the ATTUNE Total
Knee System, JOHNSON & JOHNSON: DEPUY SYNTHES (Jan. 19, 2021),
https://www.jnjmedicaldevices.com/en-US/news-events/depuy-synthes-receives
-510k-fda-clearance-velys-robotic-assisted-solution-designed. DePuy Synthes is
“the Orthopaedics Company of Johnson & Johnson.” DEPUY SYNTHES,
https://www.jnjmedicaldevices.com/en-US/companies/depuy-synthes
(last
visited Mar. 14, 2022).
38. Hugo RAS System, MEDTRONIC, https://www.medtronic.com/covidien
/en-us/robotic-assisted-surgery/hugo-ras-system.html (last visited Mar. 14,
2022).
39. In 2008, Hansen Medical’s Sensei robotic system cost $675,000, and the
da Vinci system cost $1.3 million. Barnaby J. Feder, Prepping Robots To
Perform Surgery, N.Y. TIMES (May 4, 2008), https://www.nytimes.com/2008/05
/04/business/04moll.html. Medical institutes often pay additional amounts to
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criticisms of the da Vinci series involve its costly price to equip,
its system complication, and the advantages it yields over
traditional surgery methods are less significant than expected.40
Moreover, the da Vinci series has also received criticism for its
lack of versatility and relatively limited surgical field
applications.41 These problems are correlated––a single robotic
surgery system capable of treating a larger variety of complex
procedures reduces the number of surgical systems a healthcare
entity needs to install and the amount of time necessary for
training physicians, thereby significantly lowering costs for the
healthcare entity.42
Robotic surgery innovators now aim to make their devices
and systems more general-purpose to address these issues.43
Older robotic surgery devices like ASEOP, ZEUS, and the early
da Vinci Standard systems focused on a specific surgical
technique or medical treatment for which the technology could
most adequately provide surgical control.44 For example, the
early da Vinci systems specialized in particular laparoscopic
surgery procedures that involve visualization and tissue
retraction.45 Intuitive Surgical’s continued research efforts
train physicians to use robotic surgery systems on top of the system’s initial
price. See id.
40. See Tsuyoshi Kaneko et al., Robotic Surgery for Mitral Valve Disease,
in ROBOTIC SURGERY 111, 119 (Go Watanabe ed., 2014) (“Despite [an] optimistic
view, many surgeons [may not adopt these systems due to] concern[s] with the
complexity and procedure cost . . . .”).
41. Gyu-Seog Choi, Lateral Pelvic Node Dissection for Advanced Rectal
Cancer: Current Debates and Use of the Robotic Approach, in ROBOTIC SURGERY
75, 76 (Go Watanabe ed., 2014) (“Unfortunately, the da Vinci robotic system also
comes with disadvantages, including limited range of surgical field, an intuitive
but not versatile approach, and high costs.”).
42. See U. Hagn, et al., The DLR MIRO: A Versatile Lightweight Robot for
Surgical Applications, 35 INDUS. ROBOT: INT’L J. 324, 324 (2008) (“Specialized
[robotic] systems . . . like . . . the da Vinci surgical system . . . can fulfil[l] the
dedicated task very well, but link the financial amortization in the clinic to
single medical procedures.”).
43. According to German Aerospace Center (DLR) researchers, the older
“specialized” systems designed for specific techniques or treatments are being
phased out by “versatile” systems that can operate in various surgical
applications and special settings. Id.
44. See id.; see also George et al., supra note 17, at 1, 7, 9–10 (giving a
comprehensive history of robotic surgery device evolution).
45. M.E. Hagen & M.J. Curet, Development of Robotic Systems, in ROBOTIC
SURGERY 21, 22–23 (Go Watanabe ed., 2014); see also Ann Marie McGuiness,
Robotics in Minimally Invasive Surgery, SURGICAL TECHNOLOGIST, Dec. 2000,
at 11, 14 (detailing how the da Vinci system works and its surgical applications).
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expanded use of robotic devices to other surgery fields, including
neurosurgery, orthopedics, and urology.46 The latest da Vinci SP,
for instance, specializes in urological surgeries in addition to its
traditional gastrointestinal uses.47 Intuitive Surgical’s
competitors have also put significant efforts into developing
more versatile and general-purpose robotic surgery systems. For
example, German Aerospace Center (DLR) developed DLR
MIRO, a versatile and lightweight surgical robotic system.48 The
MIRO robot is designed to “fit seamlessly into existing surgical
procedures and clinical environments” and to “comply with
rapidly changing development in medical treatment and
safety.”49 Thus, the trend towards future general-purpose
robotic surgery technology is apparent.
B. ADMINISTRATIVE REGULATION OF ROBOTIC SURGICAL
DEVICES AND SYSTEMS
Surgeons use robotic surgical devices and systems in
procedures that preserve human lives. Administrative
regulation of robotic surgical devices is necessary to protect
public health but must be carefully balanced to not stifle
technological innovation.50 Many countries have not established
“Tissue retraction” is a surgical term of art, roughly defined as holding back
tissue for the surgeon’s access and line of sight, or to prevent damage to
surrounding structures. See generally P.R.C. Steele et al., Current and Future
Practices in Surgical Retraction, 11 SURGEON 330, 330, 333–34 (2016)
(reviewing different forms of retraction methods).
46. Hagen & Curet, supra note 45, at 24–25. “So far, more than 2,300 da
Vinci systems have been installed worldwide. Many kinds of surgical
operations, such as general surgery, gynecologic surgery, urologic surgery,
pediatric surgery, cardiothoracic surgery, and other operations were performed
using the da Vinci Surgical System.” Ohuchida & Hashizume, supra note 16, at
2 (internal citations omitted).
47. Thom E. Lobe, Da Vinci SP Surgical System, EndoWrist SP
Instruments, and Accessories, SAGES (July 29, 2019), https://www.sages.org
/publications/tavac/da-vinci-sp-surgical-system-endowrist-sp-instruments-andaccessories.
48. Hagn et al., supra note 42, at 324. The new generation MIRO DLR
included a “compact, slim and lightweight robot (LWR) arm.” Id. The DLR
researchers considered this arm a “versatile core component for various existing
and future medical robotic procedures,” whereas previous systems used
components with a “stiff structure[] and relatively high mass” like those used
in industrial robots. Id.
49. Id. at 325.
50. See Ronald Leenes et al., Regulatory Challenges of Robotics: Some
Guidelines for Addressing Legal and Ethical Issues, 9 L. INNOVATION & TECH.
1, 7 (2017) (“Another, related, dilemma presents itself in the regulation of
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a clear regulatory framework for robotic surgical devices and
systems, as the technology only appeared in the commercial
market less than twenty years ago and has been developing at a
rapid speed.51 Many countries choose to treat robotic surgical
devices as a subcategory of medical devices and systems,
applying corresponding regulations.52 The United States is one
such country.
1. Approval and Clearance Regulation
In the United States, robotic surgery devices and systems,
like other medical devices, must be reviewed by the United
States Food and Drug Administration (FDA) before entering into
commercial markets.53 Device regulation started in the United
States after enactment of the Medical Device Amendments of
1976, which modified the Federal Food, Drug, and Cosmetic Act
(FFDCA).54 The 1976 Amendments stipulate a risk-based
regulation scheme for medical devices.55 Specifically, the FDA
established a scheme that classifies medical devices depending
on the device’s intended use and indicated use according to the
device’s labeling.56 So far, the FDA has established
classifications for approximately 1,700 different generic types of
emerging technologies. On the one hand, we have the concern that premature
and obtrusive legislation might hamper scientific advancement and prevent
potential advantages from materialising, and burden competitiveness or cause
economic or other inefficiencies. At the same time, somehow paradoxically, the
lack of a reliable and secure legal environment may equally hinder technological
innovation.”).
51. See id. For example, the European Union has no specific regulation for
robotic surgery system like the da Vinci. Id. at 8.
52. The European Union, for instance, regulates da Vinci as a Class IIb
medical device based on Annex IX of the Medical Devices Directive (MDD). Id.
(citing Council Directive 93/42/EEC, annex IX, 1993 O.J. (L 169) (EC)).
“Surgical robots[] . . . are treated no different than other medical devices used
in surgical operations, such as scissors and scalpels. The MDD solely regulates
the function, design and construction requirements of medical devices and not
the risks involved in robot surgery, which are determined by a complex humanmachine interplay.” Id. at 9.
53. 21 U.S.C. § 360(c). The FDA’s Center for Devices and Radiological
Health (CDRH) is responsible for medical device review. JUDITH A. JOHNSON,
CONG. RSCH. SERV., R42130, FDA REGULATION OF MEDICAL DEVICES 1 (2016).
54. Medical Device Amendments of 1976, Pub. L. No. 94-295, 90 Stat. 539
(1976) (codified at 21 U.S.C. § 360).
55. 21 U.S.C. § 360(h)(2).
56. Classify Your Medical Device, U.S. FOOD & DRUG ADMIN., https://www.
fda.gov/medical-devices/overview-device-regulation/classify-your-medicaldevice (last visited Mar. 14, 2022).
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devices and grouped them into sixteen panels.57 Medical devices
are divided into three regulatory classes based on intrinsic
risk—Classes I, II, and III (in order from lowest to greatest
risk)—each of which entails different FDA approval
requirements.58 Most robotic surgery systems fall into Class III,
as they are deemed as “those that support or sustain human life,
are of substantial importance in preventing impairment of
human health, or which present a potential, unreasonable risk
of illness or injury.”59 The FFDCA provides two main paths––
namely, premarket approval approach and 510(k) approach––for
Class III medical device manufacturers to bring such devices to
market.60 The premarket approval approach consists of two
steps––conducting clinical studies to generate evidence
providing a reasonable assurance that a device new to the
market is safe and effective, and submitting a premarket
approval application containing such evidence to the FDA.61 The
premarket approval results in FDA approval of a novel device.62
The 510(k) approach, on the other hand, requires submitting a
premarket notification through the “510(k) process” if the
manufacturer intends to introduce a device substantially
equivalent to another device already on the market, or if the
manufacturer seeks a new indication (e.g., a new population, a
new disease, or a new condition) for a currently marketed
device.63 The 510(k) process thus results in FDA clearance,
rather than approval.64 Compared to the premarket approval

57. Id.
58. Id.
59. 21 C.F.R. 814; Premarket Approval,
U.S. FOOD & DRUG ADMIN.
[hereinafter PMA], https://www.fda.gov/medical-devices/premarketsubmissions/premarket-approval-pma#when (last visited Nov. 28, 2020).
60. Johnson, supra note 53, at Summary.
61. Id.
62. Id.
63. Id. at 19–20. Some Class III pre-amendment devices may require a
Class III 510(k). For details regarding 510(k) process, see 510(k) Clearances,
U.S. FOOD & DRUG ADMIN., https://www.fda.gov/medical-devices/deviceapprovals-denials-and-clearances/510k-clearances (last visited Nov. 28, 2020).
63. Johnson, supra note 53, at 19–20.; see also Premarket Notification
510(k), U.S. FOOD & DRUG ADMIN., https://www.fda.gov/medical-devices
/premarket-submissions-selecting-and-preparing-correct-submission
/premarket-notification-510k (last visited Mar. 24, 2022) (discussing
circumstances when a 510(k) is required).
64. Johnson, supra note 53, at 19–20.
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approach, the 510(k) process is much less rigorous,65 much less
expensive, and much less time-consuming, and therefore is
favored by robotic surgery device and system manufacturers.66
As an alternative to premarket approval application and normal
510(k) process, a third track called the De Novo classification
applies to innovative devices which pose health risks that stand
between the levels required by premarket approval application
and normal 510(k) process.67 Theoretically, the De Novo
classification provides a “failsafe position” for novel medical
devices which were automatically placed in Class III after
receiving a “not substantially equivalent” determination in
response to a 510(k) submission.68 Nonetheless, empirical
studies show that in practice, surgery devices and systems
suppliers rarely seek De Novo review compared to the other two
pathways.69
As indicated above, obtaining FDA clearance and approval
for medical devices takes time. The FDA approval process can
take about seven years, causing significant delays in the
commercialization of a medical device.70 The FDA clearance
process for a Class III medical device itself can be shorter, taking

65. In his report, Johnson stated three characteristics of the 510(k) process
contribute to this difference: (1) the FDA generally does not require premarket
inspections of how devices were manufactured; (2) the FDA does not require
post-market studies as a condition of clearance; and (3) the FDA has limited
authority to rescind or withdraw clearance if a 510(k) device is not safe or
effective. Johnson, supra note 53, at 20.
66. Id. at Summary.
67. The De Novo classification was added by the Food and Drug
Administration Modernization Act of 1997. Evaluation of Automatic Class III
Designation (De Novo) Summaries, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/about-fda/cdrh-transparency/evaluation-automatic-classiii-designation-de-novo-summaries (last visited Jan. 16, 2021).
68. Id.
69. David Britton, Automating Surgery: The Law of Autonomous Surgical
Robots, J.L. TECH. TEX. (May 1, 2016), http://jolttx.com/2016/05/01/automatingsurgery-law-autonomous-surgical-robots/#_ftnref35.
70. See Gail A. Van Norman, Drugs, Devices, and the FDA: Part 1: An
Overview of Approval Process for Drugs, JACC: BASIC TO TRANSLATIONAL
SCIENCE 170, 170 (Apr. 2016) (“New drug and device approval in the United
States take an average of 12 and 7 years, respectively, from pre-clinical testing
to approval. Costs for development of medical devices run into millions of
dollars . . . .”); Hagen & Curet, supra note 45, at 25 (mentioning that the lengthy
FDA approval process caused significant delays in the commercialization of the
first surgical robot ROBODOC).
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between one week and eight months.71 Yet it could take years for
medical device designers and manufactures to gather the
necessary data to meet the FDA requirements for submission.
Intuitive Surgical’s struggle to obtain FDA approval and
clearance for its da Vinci surgical systems tells the story.
Intuitive Surgical first obtained FDA approval and clearance in
1997, but only for visualization and tissue retraction.72 It was
not until 2000 that the device’s full instrumentation could be
used for general laparoscopic surgery indications including
cholecystectomy and Nissen fundoplication.73 In 2002, the FDA
approved the da Vinci surgical system for mitral valve surgery
and atrial septal defect (ASD) repair.74 Intuitive Surgical has
kept spending efforts on having its da Vinci cleared for a larger
variety of surgeries ever since.75
2. Label and Labeling Regulation
Another important administrative regulation on robotic
surgery systems is related to labels and labeling.76 All FDAapproved or -cleared medical devices, including robotic surgery
systems, must contain a label that adequately informs a user of
proper uses of the device and complies with labeling
requirements developed by the FDA.77 The FFDCA defines a
“label” as “a display of written, printed, or graphic matter upon
the immediate container of any article . . . .”78 Title 21 of the
Code of Federal Regulations (C.F.R.) prescribes labeling
regulations for medical devices.79 Note that labeling is a concept
71. See EMERGO, HOW LONG IT TAKES THE US FDA TO CLEAR MEDICAL
DEVICES VIA THE 510(K) PROCESS (Mar. 2017) (showing that it takes an average
of five months for 510(k) submission to clear, and that different types of devices
have different clearance times).
72. George et al., supra note 17, at 10.
73. George et al., supra note 17, at 10; Hagen & Curet, supra note 27, at
11.
74. Go Watanabe, Cardiac Surgery: Overview, in ROBOTIC SURGERY 87, 92
(Go Watanabe ed., 2014).
75. See George et al., supra note 17, at 10.
76. Johnson, supra note 53, at 40.
77. Id.; see also DIV. OF SMALL MFRS. ASSISTANCE OFF. OF TRAINING &
ASSISTANCE, LABELING: REGULATORY REQUIREMENTS FOR MEDICAL DEVICES
43 (1989), https://www.fda.gov/media/74034/download.
78. 21 U.S.C. § 321(k) (1938).
79. See Device Labeling, U.S. FOOD & DRUG ADMIN. (Oct. 23, 2020),
https://www.fda.gov/medical-devices/overview-device-regulation/devicelabeling.
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different from a label. The FFDCA defines “labeling” as “all
labels and other written, printed, or graphic matter (1) upon any
article or any of its containers or wrappers, or (2) accompanying
such article at any time while a device is held for sale after
shipment or delivery for shipment in interstate commerce.”80
The FDA and courts have held the view that “most, if not all
advertising, is labeling.”81 Accordingly, advertising on medical
devices must comply with relevant FDA regulations on labeling.
Medical devices must conform to the general device labeling
requirements under 21 C.F.R. § 801.82 Several relevant
requirements are discussed in the following. Specifically, § 801.1
stipulates that the label of a device shall contain necessary
information of its manufacturers, packers, or distributors such
as their names and addresses.83 Section 801.4 requires
disclosure of intended uses for the device, which are determined
by the “objective intent of the persons legally responsible for the
labeling of [devices].”84 Such persons should provide adequate
labeling to their best knowledge in accordance with all uses for
conditions or purposes other than those intended.85 Section
801.5 asks for adequate directions under which a layman can
safely use a device for its intended purposes.86 Of note,
theoretically, robotic surgery systems and devices are exempted
from this particular requirement as they require assistance from
practitioners.87 Section 801.6 requires labeling of a device not to
contain any false or misleading statement “with respect to
another device or a drug or a food or cosmetic.”88 Furthermore,
80. Id.; 21 U.S.C. § 321(m) (1938).
81. DIV. OF SMALL MFRS. ASSISTANCE OFF. OF TRAINING & ASSISTANCE,
supra note 77, at 3 (“The distinction between labeling and advertising . . . is
often superficial or nebulous . . . . Congress did not, and we cannot, exclude from
the definition printed matter which constitutes advertising.”).
82. 21 C.F.R. § 801 (2022). “All devices must conform to the general labeling
requirements,” while “[c]ertain devices require specific labeling.” Johnson,
supra note 53, at 36 (citation omitted). These devices do not include robotic
surgery devices and systems. See id. at 36 n. 232.
83. 21 C.F.R. § 801.1 (2022).
84. 21 C.F.R. § 801.4 (2022).
85. See DIV. OF SMALL MFRS. ASSISTANCE OFF. OF TRAINING & ASSISTANCE,
supra note 77, at 5 (using a manufacturer of dental X-ray equipment who is
routinely selling his product to podiatrists as an example).
86. 21 C.F.R. § 801.5 (2022).
87. See 21 C.F.R. § 801.109 (2022); see also DIV. OF SMALL MFRS.
ASSISTANCE OFF. OF TRAINING & ASSISTANCE, supra note 77, at 8.
88. 21 C.F.R. § 801.6 (2022).
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many robotic surgery systems and devices also need to meet
labeling requirements for investigational devices and 510(k)
devices, if such a system or device is “the object of a clinical
research or investigation,”89 or is undergoing a 510(k) clearance
process.90 The format for the 510(k) submission is outlined in §§
807.81 to 807.91.91
The FFDCA urges developers, manufacturers, and sellers to
label their medical device products properly and adequately. The
FDA warns that “there is often a direct relationship between
device misuse and the labeling, especially in the directions for
use.”92 Medical device firms must take into consideration both
who will be using the device and how it will be used in order to
draft suitable labeling and avoid certain problems the law is
designed to prevent.93 Finally, it is noted that although
misbranding and poor label control violate the letter of the law,94
inadequate labeling, though potentially problematic, does not
always result in violation of the FFDCA.95
C. PATENT INFRINGEMENT LAWSUITS AGAINST ROBOTIC
SURGERY COMPANIES AND THE HIGH RISK OF SECONDARY
LIABILITY ARISING OUT OF INDIRECT INFRINGEMENT
The costs to comply with multiple countries and areas’
administrative regulations have already placed substantive
burdens, necessary or not, on robotic surgery companies.96 The
frequent need to deal with patent infringement accusations, if
existing, will certainly drag robotic surgery system developers’
innovation incentives further down.

89. DIV. OF SMALL MFRS. ASSISTANCE OFF. OF TRAINING & ASSISTANCE,
supra note 77, at 15.
90. See id. at 16.
91. Id.
92. DIV. OF SMALL MFRS. ASSISTANCE OFF. OF TRAINING & ASSISTANCE,
supra note 77, at 37.
93. Id. at 37.
94. Misbranding and false or misleading labeling are proscribed by § 502 of
the FFDCA. Id. at 3–4. 21 C.F.R. § 820 demands good manufacturing practices
from medical device suppliers and proscribes poor label control. Id. at 18.
95. Id. at 37.
96. See, e.g., Johnson, supra note 53, at Summary; Adam Lewin, Medical
Device Innovation in America: Tensions Between Food and Drug Law and
Patent Law, 26 HARV. J.L. & TECH. 403 (2012).
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1. Patent Infringement Lawsuits, Frivolous or Not, Cost
Significant Amounts of Time and Money to Resolve.
The complexity and sophistication of both the legal and
technical aspects of patent infringement disputes determine
whether a dispute could persist for years or even decades.
Professor Mark A. Lemley has demonstrated in his article Where
to File Your Patent Case that the trial time in district court alone
could vary from 0.67 years to 3.51 years.97 If any party appeals,
the span of the suit could easily stretch to more than five years.98
In an exceptional case, Grain Processing Corp. v. American
Maize-Products Co.,99 the dispute spanned more than eighteen
years and nine judicial opinions.100
While costs for litigating patent infringement matters surge
along with length of the suit, it is still not comparable to the
potential loss to the accused resulting from remedies that a court
would award the patent owner. Sections 283 and 284 of Title 35
of the United States Code respectively stipulate that a court
upon finding infringement can grant a patent owner either
injunctive or monetary relief or both.101 Section 284 further
empowers a court to use its discretion to “increase the damages
up to three times the amount found or assessed” should the court
find the infringement willful or egregious.102 Section 285 further
stipulates that courts can award reasonable attorney fees to the
prevailing party in exceptional cases.103 An injunction

97. Mark A. Lemley, Where to File Your Patent Case, 38 AIPLA Q.J. 401,
416–18 (2010). In a more recent report produced by the Fish & Richardson law
firm in 2019, it was noted that in a patent case, the fact discovery period alone
may last from six months to several years and that it typically takes from one
to three years for a case to get to trial. FISH & RICHARDSON, A GUIDE TO PATENT
LITIGATION IN FEDERAL COURT 6 & 8 (Lawrence K. Kolodney ed., 2019).
98. Compare Lemley, supra note 97, at 416–19 (stating trial time in district
court can be as long as 3.51 years), with FISH & RICHARDSON, supra note 97, at
18 (showing the timeline of the appeal process).
99. 185 F.3d 1341 (Fed. Cir. 1999).
100. Id. at 1343 (“This appeal culminates the lengthy and complex history
of this case, spanning more than eighteen years and eight prior judicial
opinions, three by this court.”).
101. 35 U.S.C. §§ 283–84.
102. 35 U.S.C. § 284 (2011); Halo Electronics, Inc. v. Pulse Electronics, Inc.,
579 U.S. 93, 110 (2016) (ruling that awards of enhanced damages are to punish
and deter “willful” and “egregious” conducts and are discretionary).
103. 35 U.S.C. § 285 (1952). Similar to enhanced damages, award of attorney
fees is also a matter within a court’s discretion, and it requires the court to
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temporarily or permanently halts all activities deemed
infringing by the court, resulting in economic loss for the
accused.104 An injunction could also interrupt the accused’s
business activities leading to a loss of a market position.105 The
effect of injunctions are so powerful that Justice Kennedy
warned in his concurrence in eBay Inc. v. MercExchange,
L.L.C.106 that sometimes “the threat of an injunction is employed
simply for undue leverage in negotiations . . . .”107 Monetary
damages, which are normally calculated based on either lost
profits that the patent owner would have gained but for the
infringement or a reasonable royalty that the parties would have
successfully negotiated, could be equally, if not more, damaging
to the accused than injunctions.108 To illustrate, even the 3%
reasonable royalty rate awarded by the District Court in Grain
Processing Co. v. American Maize-Products Co. “yielded
damages of approximately $2.4 million, and the lost profits the
patent owner sought amounted up to $35 million, which with
applicable interest presently implie[d] an award approaching
$100 million.”109
Furthermore, accusations of patent infringement could
jeopardize a company’s reputation.110 Involvement in an
infringement lawsuit itself can devastate years of effort by a
company. It is not rare to see infringement lawsuits tactically
consider all circumstances and make case-by-case determinations. Octane
Fitness, LLC v. Icon Health & Fitness, Inc., 572 U.S. 545, 554 (2014).
104. Injunctions and Restraining Orders in Patent Infringement Cases,
JUSTIA,
https://www.justia.com/intellectual-property/patents/infringement
/injunctions-and-restraining-orders-in-patent-infringement-cases/ (last visited
Jan. 17, 2021).
105. Jeffri A. Kaminski, Using Injunctions to Gain Market Share: What’s the
Harm?, VENABLE LLP (June 2012), https://www.venable.com/insights
/publications/2012/06/using-injunctions-to-gain-market-share-whats-the-h.
106. 547 U.S. 388 (2006).
107. Id. at 397 (Kennedy, J., concurring). It is particularly problematic when
the patented invention is a small component of the product the companies seek
to produce, creating a scenario which patent law professionals refer to as
“patent holdup.” See THOMAS F. COTTER, REMEDIES IN U.S. PATENT LAW 9 (2d
ed.) for further discussion.
108. See COTTER, supra note 107, at 22.
109. 185 F.3d 1341, 1353 n.4 (Fed. Cir. 1999).
110. See generally Robin Feldman & Evan Frondorf, Patent Trolls and IPOs:
A Perfect Moment to Strike, COLUMBIA L. SCH. BLUE SKY BLOG (May 26, 2015),
https://clsbluesky.law.columbia.edu/2015/05/26/patent-trolls-and-ipos-a-perfect
-moment-to-strike/ (discussing the damaging effect of infringement litigation on
company valuation).
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filed or threatened against a technology company just to
sabotage its efforts in its Initial Public Offering (IPO).111
2. Robotic Surgery System Companies are Susceptible to
Indirect Infringement of Device and/or System Patents.
35 U.S.C. § 271(a) stipulates that “whoever without
authority makes, uses, offers to sell, or sells any patented
invention, within the United States or imports into the United
States any patented invention during the term of the patent
thereof, infringes the patent.”112 In addition, § 271(b) further
stipulates that a party can be held liable for actively inducing a
third-party’s infringement, and § 271(c) yields that a party who
contributes to a third-party’s infringement is likewise liable.113
The infringement theory under § 271(a) is commonly referred to
as “direct infringement,” as the party directly infringes.114 In
contrast, the infringement theory under §§ 271(b) and (c) are
commonly referred to as “indirect infringement.”115 Together,
the three statutes constitute the most commonly-used patent
infringement theories.
In practice, when the claimed subject matter in a patent is
a device and a supplier makes, manufactures, sells, or imports
into the United States a robotic surgery system that is entirely
or partially the same or is an equivalent to the claimed device,116
the device patent owner can sue the supplier for directly
infringing the patent. Alternatively, the device patent owner can
sue the supplier for contributing to or inducing the infringing
use of the claimed device by medical practitioners in
corresponding medical procedures.

111. See id. (discussing the intriguing relationship between IPOs and
patents (citing Certco Inc. v. PayPal Inc., Civil Action No. 02-094 (D. Del. Feb.
4, 2002), available at http://www.sec.gov/Archives/edgar/data/1103415/0000912
05702004798/a2070244zex-99_2.htm)).
112. 35 U.S.C. § 271(a).
113. 35 U.S.C. §§ 287(b) and (c).
114. See, e.g., Aro Mfg. Co. v. Convertible Top Replacement Co., 377 U.S.
476, 483 (1964) (referring to infringement under § 271(a) as “direct
infringement”).
115. See id.
116. In order to ensure the enforcement of patents, one also infringes under
the “doctrine of equivalents,” which requires a comparison between each feature
of the accused product and the claimed invention. See Warner-Jenkinson v.
Hilton Davis Chem. Co., 520 U.S. 17 (1997).
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Usually, the device patent owner will simply list direct
infringement and indirect infringement together in a complaint
as alternative theories. The following case reflects such a
common scenario. On March 15, 2019, P Tech, LLC117 filed a
complaint against Intuitive Surgical in the United States
District Court for the District of Delaware, contending that
Intuitive Surgical’s selling of the da Vinci surgical system with
Endo Wrist Staplers and SureForm Staplers directly and
indirectly infringed two of its patents—U.S. Patent Nos.
9,149,281 and 9,192,395, respectively.118 Specifically, P Tech
alleged that the Endo Wrist Stapler and SureForm Staplers
Intuitive Surgical used in its da Vinci surgical systems
correspond to the claimed inventions in its two device patents,
thereby rendering the making and selling of da Vinci surgical
systems direct infringement of the two device patents.119 In
addition, P Tech alleged that Intuitive Surgical “facilitat[es],
train[s], support[s], teach[es], direct[s], and instruct[s]” its
customers and/or end-users, who are the healthcare providers at
healthcare entities, to use the da Vinci surgical systems
equipped with the allegedly infringing Endo Wrist Staplers
and/or SureForm Staplers, thereby indirectly infringing its two
patents under §§ 271(b) and (c).120
In such cases, the accuser ties its indirect infringement
charges to its direct infringement charges and strategically lists
them as alternative infringement theories in complaint. Because
the indirect infringement claims rise and fall with the direct
infringement claims, the risk of indirect patent infringement
arising out of medical procedures performed by third parties for
a robotic surgery system supplier is therefore at least the same
as the risk of direct infringement when the patent at issue covers
devices or systems.
3. Robotic Surgery System Companies are Also Susceptible to
Indirect Infringement of Medical Treatment Method Patents.
Somewhat counterintuitively, under current United States
patent law, a robotic surgery system supplier, like all medical
117. P Tech, BONUTTI TECHNOLOGIES, https://bonuttitechnologies.com
/designs/p-tech/ (last visited Dec. 5, 2020).
118. Complaint at 19, P Tech, LLC v. Intuitive Surgical, Inc., DED-1-99-cvde460 (D. Del. Mar. 18, 2019).
119. Id. at 7–18.
120. Id.
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device or system suppliers, could indirectly infringe a medical
treatment method patent.121 In fact, controversy has long
surrounded whether patent protection should extend to medical
treatment methods, and if so, to what extent.122 The Agreement
on Trade-Related Aspects of Intellectual Property Rights (TRIPS
Agreement) permits World Trade Organization (WTO) member
countries to exclude medical treatment methods from
patentability, but leaves the decision to the countries.123 To not
overly burden physicians as they seek to administer the best
available treatment for patients, four of the “IP5”124 jurisdictions
choose to hold that medical procedures are per se
unpatentable.125 The United States chooses to allow medical

121. As demonstrated below, 35 U.S.C. §§ 271(b) and (c) apply here with
limitation in § 287(c).
122. See, e.g., Bradley J. Meier, The New Patent Infringement Liability
Exception for Medical Procedures, 23 J. LEGIS. 265, 265 (1997).
123. TRIPS: Agreement on Trade-Related Aspects of Intellectual Property
Rights, Apr. 15, 1994, Marrakesh Agreement Establishing the World Trade
Organization, Annex 1C, 1869 U.N.T.S. 299, 33 I.L.M. 1197, Art. 27(3)(a) (1994)
(permitting but not requiring member countries to exclude from patentability
“diagnostic, therapeutic and surgical methods for the treatment of humans or
animals”).
124. “IP5” stands for the five largest intellectual property offices in the
world, including the United States Patent and Trademark Office (USPTO), the
European Patent Office (EPO), the Japan Patent Office (JPO), the Korean
Intellectual Property Office (KIPO), and the China National Intellectual
Property Administration (CNIPA). See FIVE IP OFFICES, https://www.fiveip
offices.org/index (last visited Nov. 28, 2020).
125. Convention on the Grant of European Patents, Oct. 5, 1973, 1065
U.N.T.S. 199, art. 52(4) (excluding “methods for treatment of the human or
animal body by surgery or therapy and diagnostic methods practiced on human
or animal body” from patentable subject matter); JAPAN PATENT OFFICE,
EXAMINATION GUIDELINES FOR PATENT AND UTILITY MODEL IN JAPAN, Pt. III,
Ch. 1, at 8, https://www.jpo.go.jp/e/system/laws/rule/guideline/patent/tukujitu
_kijun/document/index/03_0100_e.pdf (last visited Nov. 28, 2020) (providing
that methods of surgery, therapy, or diagnosis of humans do not meet the
industrial applicability requirement under Japanese patent law main
paragraph of art. 29(1)); KOREAN INTELLECTUAL PROPERTY OFFICE, PATENT
EXAMINATION GUIDELINES, Pt. III, Ch. 1(5), https://www.kipo.go.kr/upload/en
/download/patent_examination_guidelines_2018_01.pdf (last visited Nov. 28,
2020) (“A method for treatment of the human body by surgery or therapy and a
diagnostic method practiced on the human body are considered to be
industrially inapplicable inventions.”); WORLD INTELLECTUAL PROPERTY
OFFICE, PATENT LAW OF THE PEOPLE’S REPUBLIC OF CHINA, art. 25(3),
https://www.wipo.int/edocs/lexdocs/laws/en/cn/cn028en.pdf (last visited Nov.
28, 2020) (“Patent rights shall not be granted for . . . methods for the diagnosis
or treatment of diseases.”). Note, however, jurisdictions may provide some
“work-arounds” while banning patents on medical methods. For example, the
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procedures as patentable subject matter.126 However, to counter
potential harshness this rule might bring to the country’s health
care system, under legislation enacted in 1996, 35 U.S.C. §
287(c) provides severe limits on remedies for infringing such
patents.127 Specifically, § 287(c)(1) stipulates that patent owners
cannot get any remedy against a “medical practitioner” as
defined in § 287(c)(2)(B) with respect to his or her performance
of a medical activity or a “related health care entity” as defined
in § 287(c)(2)(C), encompassing the responsible doctors, nurses,
and related health care entities.128 The law, however, leaves
medical method patent owners with the option to obtain
remedies from medical supply companies which make and sell
devices and systems used in the infringing medical activity,129
even though the medical practitioners who directly infringe the
patented medical methods are exempted from liabilities. A
medical procedure patent owner thus can sue the medical
equipment suppliers for actively inducing and/or contributing to
the medical practitioners’ infringing performance of the
patented procedure under §§ 271(b) and (c).130

EPO generally allows second medical use claims using a format such as
“compound X for use in the treatment of disease Y.” Convention on the Grant of
European Patents, Oct. 5, 1973, 1065 U.N.T.S. 199, art. 54(5).
126. 35 U.S.C. § 101 stipulates that patentable subject matter includes
“process, machine, manufacture, or composition of matter.” Medical procedures
are deemed a “process.” See Lara L. Douglass, Medical Process Patents: Can We
Live Without Them? Should We?, 3 J. INTELL. PROP. L. 161, 161–62 (1995).
There is no law in the United States providing that medical procedures are
unpatentable subject matter.
127. In the mid-1990s, Dr. Samuel Pallin first tried to enforce his patent on
the method of making incisions in performing eye surgery, inducing outrage in
the health care community and public. In response, Congress passed what is
encoded as § 287(c). 35 U.S.C. § 287(c). See ROBERT PATRICK MERGES & JOHN
FITZGERALD DUFFY, PATENT LAW AND POLICY 169–71 (7th ed. 2017).
128. To counter the harshness that allowing medical procedures to be
patented brings to health care systems, Congress passed the bill in 1996 to add
§ 287(c) mainly to provide immunity for health care providers. 141 CONG. REC.
15290-07 (Oct. 18, 1995) (statement of Sen. Frist) (acknowledging that issuance
of patents on medical procedures conflicts with the broader social interest in
providing health care); see also Leisa Talbert Peschel, Revising the Compromise
of 35 U.S.C. § 287(c), 16 TEX. INTELL. PROP. L.J. 299, 308–10 (2008) (describing
the legislative process of the statute).
129. See MERGES & DUFFY, supra note 127, at 171.
130. 35 U.S.C. §§ 271(b)–(c). Note the Supreme Court has held that to find
indirect infringement, there must be direct infringement under § 271(a). Aro
Mfg. Co. v. Convertible Top Replacement Co., 365 U.S. 336, 340–42 (1961).
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In Barry v. Medtronic, Inc.,131 the medical procedure patent
owner Dr. Mark Barry successfully asserted induced
infringement of medical method claims in two patents against
the medical device producer and seller Medtronic.132 In this case,
Dr. Barry asserted that surgeons, who were practicing spinal
derotation procedures with Medtronic’s Vertebral Colum
Manipulation (KCM) kit,133 directly infringed his two patents
claiming a method of aligning spinal vertebrae to correct
common spinal deformities like scoliosis.134 Dr. Barry accused
Medtronic of induced infringement by supplying the surgeons
with its KCM kits and providing extensive training materials
and instructions relating to the KCM kit.135 The District Court
found Medtronic liable for inducing surgeons to use its devices
to infringe Barry’s patents.136 The District Court thus ordered
Medtronic to pay Dr. Barry $21,265,416 in damage, including a
20% enhancement of the final damages for the willfulness in its
infringement.137 Medtronic unsuccessfully appealed to the
United States Court of Appeals for the Federal Circuit,
challenging the validity of the claims at issue.138 The Federal
Circuit eventually affirmed the District Court’s ruling.139
Medtronic petitioned to the United States Supreme Court, and
on January 13, 2020, the Court denied certiorari, making the
judgement final.140
Different from indirect infringement on device and system
patents discussed in Part I.C.2. above, indirect infringement on
method patents is usually asserted alone without direct
infringement assertion.141 The indirect infringement theory
advanced by Dr. Barry appeals to medical treatment method

131. 914 F.3d 1310 (Fed. Cir. 2019).
132. Id.
133. Id. at 1310–20.
134. U.S. Patent No. 7,670,358 (filed Mar. 2, 2010); U.S. Patent No.
8,361,121 (filed Jan. 29, 2013).
135. Id.
136. Barry v. Medtronic, Inc., 250 F. Supp. 3d 107 (E.D. Tex. 2017).
137. Id.
138. Barry v. Medtronic, Inc., 914 F.3d 1310 (Fed. Cir. 2019).
139. Id.
140. Medtronic, Inc. v. Barry, 2020 U.S. LEXIS 17 (U.S., Jan. 13, 2020).
141. As previously stated, § 287(c)(1) limits recovery from a directly
infringing “medical practitioner” but leaves recovery open for induced
infringement. As an aside, it is also likely bad public relations for a company to
sue doctors.
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patent owners, as they only have limited choices in enforcing
their patent rights under the current United States patent law.
Although patent applicants have paid less attention to
protecting medical treatment method patent rights due to the
limitations § 287(c) imposes, Dr. Barry’s success likely brings
medical treatment method patent enforcement back to patent
owners and applicants’ attention, which could in turn result in a
surge in medical treatment method patent owners enforcing
their rights against medical device and system suppliers.142
4. The Problem of Various Indirect Infringement Liabilities
Concern Robotic Surgery System Suppliers Even More than
Other Medical Device Suppliers.
Although the various secondary liabilities discussed in
Parts I.C.2. and 3. present a problem universal to medical
devices, the risk of facing indirect infringement charges
increases for robotic surgery system suppliers due to the
increased complexity of such systems compared with other
medical devices. A robotic surgery system usually incorporates
multiple surgical tools and means for controlling the surgical
tools to perform designed medical procedures.143 The complex
structure of the da Vinci surgical system illustrates this point.
Specifically, all da Vinci surgical systems comprise a surgical
console, a surgical cart, and a vision cart, wherein the surgical
cart comprises multiple mechanical arms holding a camera and
surgical instruments that a surgeon remotely controls from the
surgical console.144 Theoretically, patents could exist for each
instrument in the robotic surgery system and its corresponding
use in medical procedure. As a result, the total number of
patents a robotic surgery system could possibly infringe
142. Joey Moussa & Doug Portnow, Protecting Medical Method Patents via
Indirect Infringement, LAW360 (Aug. 14, 2019, 1:05 PM), https://www
.law360.com/articles/1188364/protecting-medical-method-patents-via-indirectinfringement (stating that medical method claims have been neglected by many
patent applicants, and calling to patent owners and applicants’ attention that
medical method patents can be enforced under indirect infringement theories
in view of Barry v. Medtronic).
143. Computer-Assisted Surgical Systems, supra note 11 (describing that
RAS devices generally include a bedside cart including multiple hinged
mechanical arms, camera, and surgical instruments, a console as a control
center for the surgeon to view the field and control movement of surgical
instruments, and a separate cart containing supporting hardware and
software).
144. Hagen & Curet, supra note 27, at 11–13.
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increases. Accordingly, the risk of directly or indirectly
infringing one’s patent for a robotic surgery system supplier
increases.
D. ROBOTIC SURGERY SYSTEM COMPANIES’ CURRENT DEFENSIVE
STRATEGIES AGAINST INDIRECT INFRINGEMENT
Recognizing the risk of indirect patent infringement, and
the damages involvement in such lawsuits can have on an
innovator, many robotic surgery companies have adopted one or
more of the following approaches to cope with the problem.
1. Robotic Surgery System Companies’ Litigation Strategies in
Patent Infringement Lawsuits
When the accused robotic surgery system supplier has
decided to answer the patent infringement suit, the most
common litigation strategies adopted include noninfringement
defenses and patent invalidity challenges.145 A noninfringement
defense argues that even if the patent at issue is valid, the
accused product or process does not fall within the scope of the
patent claims.146 An invalidity defense, on the other hand,
argues that the patent claims are invalid and thus do not confer
upon the plaintiff a monopoly on the product or process.147 The
United States adopts a non-bifurcated patent litigation system
that allows assessment of infringement and validity issues
within a single court proceeding.148 In most cases, defendants try
their best arguing both.149 In Barry v. Medtronic, for example,
Medtronic challenged the validity of the patents and pleaded
noninfringement in the alternative as defenses in the district
court.150
Other than a civil court, a defendant in suit can bring patent
validity challenges in front of the United States Patent and
145. Roger Allan Ford, Patent Invalidity Versus Noninfringement, 99
CORNELL L. REV. 71, 71 (2013) (“Nearly every patent lawsuit rises or falls on
one of two defenses: invalidity or noninfringement.”).
146. Id. at 71–76.
147. Id. at 77–85.
148. Different from the United States bifurcated system, in non-bifurcated
countries like Germany and China, patent validity is adjudicated by specialized
patent courts and infringement courts operate on the presumption that the
patent in suit is valid. PAUL GOLDSTEIN & MARKETA TRIMBLE, INT’L INTELL.
PROP. L. 566 (5th ed. 2019).
149. Id. at 71.
150. Barry v. Medtronic, Inc., 250 F. Supp. 3d 107 (E.D. Tex. 2017).
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Trademark Office (USPTO). Specifically, the Leahy-Smith
America Invents Act (AIA), passed in 2011, has set up several
post-grant proceedings for parties to challenge a patent’s
validity, including inter partes review (IPR),151 post-grant
review (PGR),152 ex parte reexamination, and covered business
method proceedings.153 After enactment of the AIA, IPR and
PGR soon gained popularity for their relatively low costs and
short completion time compared to civil court invalidity
challenges.154 For example, in the patent infringement dispute
between P Tech and Intuitive Surgical mentioned in Part C.2.
above, after receiving the complaint, instead of defending in
court, Intuitive Surgical chose to rapidly file an IPR on P Tech’s
patents, which the USPTO instituted on September 11, 2020.155
On March 24, 2020, the District Court granted a stay of the
lawsuit in view of the IPR and ordered administrative closure of
the case.156
While problems including lack of certainty, lengthy
proceeding times, and passive involvement in the suit surround
all of the above-discussed litigation strategies, high cost remains
the dominant one. Raising noninfringement and invalidity
defenses in court can easily rise into millions of dollars.157
USPTO post-grant proceedings such as IPR and PGR provide

151. 35 U.S.C. § 311.
152. 35 U.S.C. § 321.
153. Leahy-Smith America Invents Act, 125 Stat. 284, § 6 (2011) (stipulating
for post-AIA post-grant proceedings including ex parte reexamination, inter
partes review, post-grant review, and covered business method proceedings).
Note, however, the covered business method is no longer available after
September 16, 2020. Id. at § 18(a)(3)(A).
154. See Brian C. Kwok & Nicolas V. Martini, Post-Grant Review is
Becoming Increasingly Popular, LAW360 (June 1, 2016, 10:32 AM),
https://www.law360.com/articles/802039/post-grant-review-is-becomingincreasingly-popular (explaining that Post-grant review proceedings are
designed to be quick, lasting no more than twelve to eighteen months, and the
PTAB’s decision regarding patentability is immediately appealable to the
Federal Circuit); Ryan Kenny, Which Invalidity Avenue to Take: Inter Partes
Review Verses Post-Grant Review, IPWATCHDOG (last updated July 31, 2018),
https://www.ipwatchdog.com/2018/07/31/which-invalidity-avenue-ipr-versespost-grant-review/id=99460/ (providing a high-level overview and comparison of
inter partes review and post-grant review).
155. Intuitive Surgical, Inc. v. P Tech, LLC, IPR2020-01687.
156. P Tech, LLC v. Intuitive Surgical, Inc., PACERMONITOR, https://www.
pacermonitor.com/public/case/27493647/P_Tech,_LLC_v_Intuitive_Surgical,_I
nc (last visited Dec. 5, 2020).
157. Kenny, supra note 154 (citing PWC’s 2012 Patent Litigation Study).
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less expensive options for bringing invalidity challenges.158 In
particular, IPR proceedings cost about ten times less than patent
invalidation in civil courts, and PGR proceedings are estimated
to be slightly more costly than IPR proceedings.159 However,
both IPR and PGR proceedings still average around $300,000 to
$350,000.160
2. Robotic Surgery System Companies’ Pre-Suit Preventive
Measures
Recognizing the devastating damage patent infringement
lawsuits can inflict upon their businesses, robotic surgery
system developers have adopted measures to reduce the number
of patent infringement accusations against them. One common
measure is holding a strong patent portfolio.161 A robotic surgery
system company often keeps a strong patent portfolio through
obtaining and maintaining patents in the United States as well
as in foreign countries. Intuitive Surgical, for instance, held
more than a thousand United States and foreign patents
covering important aspects of the da Vinci by 2012,162 and that
number continues to grow each year. One’s own patents not only
confer rights to exclude competitors and protect its most
valuable assets, but also the ability to stop others from patenting
the technology and thus block potential attacks.163 Legal
practitioners have commonly referred to such practice as
“freedom of action,” which means a company, after building its
patent portfolio, has sufficient patent or cross-license coverage
to launch a new product and is comfortable with the estimated
risk of patent infringement.164 Even in the case where an
158. See Kwok & Martini, supra note 154 (explaining the relative cost
effectiveness of PGR and IPR proceedings).
159. Id.
160. Id.
161. See Sean D. Harding, Meet the Patents: Fostering Innovation and
Reducing Costs by Opening Patent Portfolios, 11 J. BUS. & TECH. L. 199 (2016)
(explaining that many companies maintain a strong patent portfolio due to the
threat of incurring substantial costs defending and settling patent litigation
targeted against them).
162. Hagen & Curet, supra note 27, at 10.
163. See, e.g., Simon Phipps, A New Way to End the Patent Madness,
INFOWORLD (June 15, 2012, 5:00 AM), https://www.infoworld.com/article
/2617429/a-new-way-to-end-the-patent-madness.html (explaining that keeping
patents as a defense allows one to disarm patent trolls).
164. Kent Richardson & Erik Oliver, When Strategies Collide: Freedom to
Operate Clashes with Freedom of Action in Converging Industries,
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application does not eventually mature into a patent or where
the technology is disclosed without filing any patent application,
publication of the application or of the technology still
constitutes a defensive publishing or technical disclosure which
effectively blocks others from claiming rights in the
technology.165 Other common preventive measures adopted by
robotic surgery system companies focus on obtaining clearance
ahead of launching, or even developing, a new product. Legal
practitioners have commonly referred to such practices as
“freedom of operation.”166 The process of obtaining clearance
could involve conducting freedom to operate searches, obtaining
a competent legal opinion on noninfringement, negotiating
licenses from patent owners, and designing around patented
features if necessary.167
Unfortunately, like the litigation strategies discussed in
Part I.D.1. above, preventive measures are also not problemfree. First, freedom of action depends on the strength of one’s
patent portfolio.168 However, no matter how strong a patent
portfolio one keeps, it is impossible to safeguard every feature of
a highly complex system like a surgical robot. Moreover, even if
every feature of the surgical robot can be safeguarded by the
developer’s own patent portfolio, it still cannot shield the
developer from indirect infringement of medical treatment
method claims. Freedom of operation, on the other hand, relies
heavily on one’s timely and accurate identification of all
problematic patents.169 A less competent and less complete

IPWATCHDOG, https://www.ipwatchdog.com/2019/03/07/when-strategies-collide
-freedom-to-operate-vs-freedom-of-action/id=107084/ (last modified Mar. 7,
2019) (“Freedom of Action means having enough patents or enough crosslicenses such that you have the ability to launch products and are comfortable
with the risk of patent infringement.”).
165. Note that this practice, though useful in some cases, stands in sharp
contrast to keeping the technology a trade secret. IP and Business: Launching
a New Product: Freedom to Operate, WORLD INTELL. PROP. ORG. MAG. (Sept.
2005), https://www.wipo.int/wipo_magazine/en/2005/05/article_0006.html.
166. Id. (“Freedom to Operate means testing, prior to launching a product,
whether any feature will infringe anyone else’s patents.”).
167. Id.
168. Richardson & Oliver, supra note 164.
169. See WORLD INTELL. PROP. ORG. MAG, supra note 165 (“A Freedom to
Operate (FTO) analysis invariably begins by searching patent literature for
issued or pending patents, and obtaining a legal opinion as to whether a
product, process or service may be considered to infringe any patent(s) owned
by others.”).
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patent search renders any analysis based thereon useless.
Designing-around, in particular, requires accurately identifying
the possible infringement ahead of time to allow for the lengthy
R&D process. Finally, both freedom of action and freedom of
operation investigations cost significant amounts of money.170
Alternative measures that are less costly, easier to maneuver,
and yield more certainty in protection for robotic surgery system
companies against secondary infringement liability are
desirable and necessary for preserving the innovation
incentives.
II. ANALYSIS
As noted in Part I.A. above, robotic surgery innovators have
aimed at making their robotic surgery devices and systems more
general purpose.171 Researchers in medical treatment
procedures and devices have also anticipated that specialized
robotic surgery systems will likely lose their niche in the
commercial market to general purpose systems in the near
future.172 More versatile robotic surgery systems yield easier
maneuverability and significantly reduce the cost for the
implementation in hospitals.173 This Note argues that the
general purpose characteristic of a robotic surgery system
provides yet another benefit––it helps shield robotic surgery
system suppliers from indirect infringement liabilities arising in
medical procedures performed at health care entities.
A. GENERAL PURPOSE ROBOTIC SURGERY SYSTEMS PROVIDE A
POSSIBLE “LACK OF KNOWLEDGE/INTENT” DEFENSE TO INDUCED
INFRINGEMENT UNDER § 271(B) AND CONTRIBUTORY
INFRINGEMENT UNDER § 271(C) FOR THE SUPPLIERS
As a preliminary note, §§ 271(b) and (c) share the same
origin of the “overarching concept of ‘contributory
infringement.’”174 In the Patent Act of 1952, Congress designed
170. Here, fees include, but are not limited to, filing and maintaining
patents all over the world, conducting patent searches, obtaining legal opinions,
licensing fees, and designing-around R&D costs. See id. (mentioning these costs
in the context of freedom to operate).
171. See Hagn et al., supra note 42 (noting that versatile systems are gaining
favor).
172. Id.
173. Id.
174. Glob.-Tech Appliances, Inc. v. SEB S.A., 563 U.S. 754, 761 (2011).
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the sections to “‘codify in statutory form principles of
contributory infringement’ which had been ‘part of our law for
about 80 years.’”175 Though put in separate paragraphs, §§
271(b) and (c) both relate to the sale of products for others’
infringing uses.176 While paragraph (b) punishes specifically
inducement by the seller, paragraph (c) deals with the other
“usual situation in which contributory infringement arises.”177
As such, courts have long treated §§ 271(b) and (c) as containing
the same scienter requirement derived from their predecessor
contributory infringement.178 Therefore, a defense that works
through negating the scienter requirement of indirect
infringement arguably should apply equally to §§ 271(b) and (c).
1. The Finding of the Scienter Requirement of §§ 271(b) and (c)
This Part’s analysis starts with the explicit scienter
requirement in § 271(c), through analogy to which courts found
the implicit scienter requirement in § 271(b). Specifically, §
271(c) recites:
Whoever offers to sell or sells within the United States or imports into
the United States a component of a patented machine, manufacture,
combination or composition, or a material or apparatus for use in
practicing a patented process, constituting a material part of the
invention, knowing the same to be especially made or especially
adapted for use in an infringement of such patent, and not a staple
article or commodity of commerce suitable for substantial
noninfringing use, shall be liable as a contributory infringer.179

The plain language of § 271(c) explicitly requires that the
contributory infringer know that his products are for infringing
use yet he still intends infringement as the result.180 In Aro Mfg.

175. Aro Mfg. Co. v. Convertible Top Replacement Co., 377 U.S. 476, 485–86
(1964); see H.R. REP. NO. 1923, at 9 (1952) (“Paragraphs (b), (c), and (d) relate
to the subject referred to as contributory infringement. The doctrine of
contributory infringement has been part of our law for about 80 years.”); see also
P.J. FEDERICO, COMMENTARY ON THE NEW PATENT ACT 28 (1954) (“Paragraph
(b) is a broad statement and enactment of the principle that one who actively
induces infringement of a patent is likewise liable for infringement. The
Committee Report in several places refers to this paragraph as relating to
contributory infringement.”).
176. FEDERICO, supra note 175, at 27–28.
177. Id. (emphasis added) (citing H. R. REP. NO. 1923, at 9).
178. See discussion infra Part II.A.1. (providing the cases that establish the
sections have been treated as having the same scienter requirement).
179. 35 U.S.C. § 271.
180. Id.
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Co. v. Convertible Top Replacement Co. (Aro II),181 the Supreme
Court noted that Congress passed § 271(c) to codify the existing
common law contributory infringement which required
knowledge and intent of the accused.182 The Aro II Court thus
held that § 271(c) contains a scienter requirement that a violator
of § 271(c) must know that a patent exists for the product at issue
and that the product, when used by others, infringes. 183
Section 271(b) recites “[w]hoever actively induces
infringement of a patent shall be liable as an infringer.”184
Unlike § 271(c), it does not use words such as “know” or
“intent.”185 Nevertheless, even before the Supreme Court spoke
on this issue, federal courts have interpreted the statute as
requiring the same scienter requirement as § 271(c). For
example, in Hilgraeve v. Symantec,186 the Michigan Eastern
District Court ruled that § 271(b) requires knowledge/intent of
the defendant since it noted that “[a]lthough section 271(b) does
not use the word ‘knowing,’ the case law and legislative history
uniformly assert such a requirement.”187 In 2011, the Supreme
Court in Global-Tech Appliances, Inc. v. SEB S.A.188 confirmed
that the knowledge/intent requirement of § 271(b) exists through
the use of the words “induce” and “actively.”189 The Global-Tech
Court stated that:
Although the text of § 271(b) makes no mention of intent, we infer that
at least some intent is required. The term ‘induced’ means ‘to lead on;
to influence; to prevail on; to move by persuasion or influence.’ . . . The
addition of the adverb ‘actively’ suggests that the inducement must

181. 377 U.S. 476, 476 (1964).
182. Id. at 487–89 (citing old cases, such as Thomson-Houston Elec. Co. v.
Ohio Brass Co., 80 F. 712, 721 (C.A. 6th Cir. 1897), to illustrate that traditional
contributory infringement required the defendant know and intend the
infringement).
183. Id. at 488.
184. 35 U.S.C. § 271.
185. Id.
186. 272 F. Supp. 2d 613 (E.D. Mich. 2003).
187. Id. at 616 (demonstrating that the Court of Appeals for the Federal
Circuit has also constantly interpreted § 271(b) as requiring the same scienter
requirement (citing Water Techs. Corp. v. Calco Ltd., 850 F.2d 660, 668 (Fed.
Cir. 1988))).
188. 563 U.S. at 754.
189. Id. at 760.
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involve the taking of affirmative steps to bring about the desired
result . . . .190

To arrive at this interpretation, the Global-Tech Court
relied on the case law before the enactment of § 271 in the Patent
Act of 1952.191 Finding that both §§ 271(b) and (c) originated
from the “overarching concept of contributory infringement” and
together they codified that concept in the statute, the Supreme
Court used its previous interpretation of § 271(c) in Aro II to hold
that it compels the same scienter requirement for finding
liability under § 271(b).192 Later in Commil USA v. Cisco
System,193 the Supreme Court reaffirmed this scienter
requirement of finding induced infringement under § 271(b).194
2. The Criteria for Finding the Required Knowledge/Intent
Currently, no uniform test or clear-cut standard exists for
finding the knowledge/intent required by §§ 271(b) and (c).
Nevertheless, decisions by the Supreme Court and lower courts
in the past decades offer some guidance on what actions of the
accused would reveal the critical knowledge/intent and what
would not.
First, direct evidence such as cease-and-desist letters,
denial of a license, and witness testimony sheds some light on a
defendant’s knowledge and intention. For example, in Aro II, the
Supreme Court relied on the cease-and-desist letter to find that
the defendant possessed the intent and knowledge required for
contributory infringement for the infringing conduct occurring
after receipt of the letter.195 In Mentor H/S v. Medical Device

190. Id. (defining “induce” (citing Webster’s New International Dictionary
1269 (2d ed. 1945))).
191. Id. at 761 (describing cases pre-1952 as providing little clarity in
interpreting the phrase “induces infringement”).
192. See id. at 761, 765 (finding that both sections require knowledge of the
existence of the patent that is infringed (citing Aro Mfg. Co. v. Convertible Top
Replacement Co., 377 U.S. 476 (1964))).
193. 575 U.S. 632, 642 (2015) (finding that induced infringement requires
plaintiff to show that defendant knew his acts were infringing).
194. Id. at 640 (“[I]t is necessary to reaffirm what the Court held in GlobalTech.”).
195. Aro Mfg. Co. v. Convertible Top Replacement Co., 377 U.S. 476, 489–90
(1964) (“For by letter dated January 2, 1954, AB informed Aro that it held the
Mackie-Duluk patent; . . . that anyone selling ready-made replacement fabrics
for these automobiles would be guilty of contributory infringement of said
patents. Thus . . . the knowledge requirement affords Aro no defense with
respect to replacement-fabric sales made after January 2, 1954.”).
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Alliance,196 the Federal Circuit found induced infringement
based on the fact that the patent owner denied the defendant’s
request for a license at the outset.197 Therefore, direct evidence
is heavily favored in showing the knowledge/intent of a
defendant. Unfortunately, direct evidence might not exist in
every indirect infringement case. Also, direct evidence like a
cease-and-desist letter or denial of a license cannot show
knowledge/intent with respect to infringing conduct that occurs
before the event and might not help if the majority of infringing
sales have already taken place.198
Alternatively, Global-Tech holds that a plaintiff can prove
the knowledge/intent element of indirect infringement through
circumstantial evidence.199 Additionally, in Metro-GoldwynMayer Studios, Inc. v. Grokster, Ltd.,200 a frequently cited
copyright law case where the Supreme Court applied the patent
law principles of induced infringement to resolve copyright
infringement issues, the Court stated that “active steps . . .
taken to encourage direct infringement, such as advertising an
infringing use or instructing how to engage in an infringing use,
show an affirmative intent that the product be used to
infringe.”201 The same rules in MGM Studio shall apply equally
to §§ 271(b) and (c), as MGM Studio borrowed patent law
analyses to arrive at its holdings.202

196. 244 F.3d 1365, 1379 (2001) (holding that defendant committed direct,
contributory, and inducement of infringement).
197. Id. at 1379 (“Mentor established at trial that Misonix knew of the
existence of the patent because it was denied a license and received a cease-anddesist letter concerning it. Yet Misonix chose to continue selling [the infringing
product] . . . .”).
198. In Aro II, the majority of infringing sales occurred after the cease-anddesist letter. Aro Mfg., 377 U.S. at 490.
199. Glob.-Tech Appliances, Inc. v. SEB S.A., 563 U.S. 754, 774 (2011)
(“Circumstantial facts like these tend to be the only available evidence in any
event, for the jury lacks direct access to the defendant’s mind.”).
200. 545 U.S. 913, 937 (2005) (holding that the inducement rule “premises
liability on purposeful, culpable expression and conduct”).
201. See id. at 936 (citing Oak Industries, Inc. v. Zenith Electronics Corp.,
697 F. Supp. 988, 992 (N.D. Ill. 1988)).
202. See, e.g., id. at 932, 935–36 (borrowing from patent law and the
commerce doctrine, “that distribution of a component of a patented device will
not violate the patent if it is suitable for use in other ways” and that clear
expression or other affirmative steps are needed for a party to be liable for
infringement).
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Courts have admitted a variety of circumstantial evidence
in addition to those specified in MGM Studio. Of great
significance to this Note’s analysis on infringement relating to
robotic surgery systems, is the training and instruction medical
device companies provide to physicians. For example, in Barry
v. Medtronic, the Federal Circuit relied on the training provided
by Medtronic and the instructions on every accused device in the
period after patenting to rule that the jury could permissibly find
inducement.203 However, not all kinds of instructions of
infringing use suffice. The particular facts in a case matter, as
courts have adopted a case-by-case approach. In Takeda
Pharms. U.S.A., Inc. v. West-Ward Pharm. Corp.,204 the Federal
Circuit distinguished instructions merely “‘describ[ing]’ an
infringing mode” from those “‘recommend[ing]’, ‘encourag[ing],’
or ‘promot[ing]’ an infringing use, or suggesting that an
infringing use ‘should’ be performed.”205 The Takeda Court
further opined that the mere existence of direct infringement by
physicians or the mere knowledge of possible infringement by
others does not amount to inducement, since inducement
requires specific intent and affirmative actions to induce.206
Moreover, in Howmedica Osteonics Corp. v. Tranquil Prospect,
Ltd.,207 the District Court ruled and the Federal Circuit later
affirmed that the accused medical device supplier did not induce
infringement since the plaintiff failed to demonstrate precise

203. 914 F.3d 1310, 1336 (Fed. Cir. 2019) (affirming the judgement of the
District Court that Medtronic induced infringement after the issuance of Dr.
Barry’s patents).
204. 785 F.3d 625 (Fed. Cir. 2015) (holding that Takeda failed to show
sufficient evidence to support a finding of inducement).
205. Id. at 631 (citations omitted); see also Microsoft Corp. v. DataTern, Inc.,
755 F.3d 899 (2013) (ruling that simply selling a product capable of being used
in infringing manner is not sufficient to create substantial controversy
regarding inducement); GE v. Sonosite, Inc., 568 F. Supp. 2d 983 (W.D. Wis.
2008) (ruling that bare listing of features, among others, on specification sheets
that did not instruct customer to perform particular method or explain how to
do anything does not count towards inducement).
206. Takeda, 785 F.3d at 631 (citing Warner-Lambert Co. v. Apotex Corp.,
316 F.3d 1348, 1364 (Fed. Cir. 2003)).
207. 482 F. Supp. 2d 1045 (N.D. Ind. 2007), aff’d, 260 Fed. Appx. 291 (Fed.
Cir. 2008) (finding that the plaintiff failed to prove literal infringement because
he failed to show that the products met every limitation set forth in the asserted
claims).
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evidence that when a surgeon followed the supplier’s protocols
that surgeon necessarily practiced the asserted patent claim.208
Other important sources of circumstantial evidence are a
medical device or system’s FDA labels and related FDA
information. Similar to pharmaceutical products, robotic
surgery and other medical devices and systems need to obtain
FDA approval and clearance before entering the market.209 And
because the FDA classifies medicines and medical devices
relying on their intended and indicated use, FDA application
and approval materials arguably reveal infringing intent and
knowledge of manufacturers and sellers.210 Specifically, courts
have viewed a defendants’ failure to exert reasonable effort to
avoid using infringing language on product labels and FDA
applications as a tell-tale sign of intention to induce
infringement.
For example, in AstraZeneca LP v. Apotex, Inc.,211 the
District Court of New Jersey faced a lack of the defendant’s
promotional and marketing activities,212 but nevertheless found
the defendant’s “affirmative intent” by showing specific intent to
infringe through infringing language on the product label as well
as in the failure to find and use alternative, non-infringing
language for its label.213 The Federal Circuit affirmed the
district court’s reasoning.214

208. Id. at 1062–63.
209. See discussion supra Part I.B.
210. Id.
211. 623 F. Supp. 2d 579 (D.N.J. 2009), supplemented, 623 F. Supp. 2d 615
(D.N.J. 2009), aff’d, 633 F.3d 1042 (Fed. Cir. 2010).
212. Id. at 603 (discussing that Apotex produced expert testimony showing
a lack of promotional and marketing activities by Apotex).
213. Id. at 605. Defendant Apotex argued that it was forced to include the
infringing language on the label to comply with FDA’s requirement. Id. at 604.
However, Plaintiff AstraZeneca argued that Apotex could have attempted to
develop a label with alternative language which would not induce infringement.
Id. at 606. The district court sided with AstraZeneca since no evidence showed
that Apotex even made such an attempt to avoid induced infringement. Id. at
603–07.
214. Id. at 1060–61 (“This court again agrees with AstraZeneca. As
explained above, the district court’s specific intent finding was not based solely
on the proposed label, but also on Apotex’s decision to proceed with its plan to
distribute the drug despite being aware that the label presented infringement
problems.”).
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Then, the Federal Circuit reiterated in Eli Lily & Co. v. Teva
Parenteral Medicines, Inc.,215 that “[d]epending on the clarity of
the instructions, the decision to continue seeking FDA approval
of those instructions may be sufficient evidence of specific intent
to induce infringement.”216 The Federal Circuit also stated that
“‘vague’ instructions that require one to ‘look outside the label to
understand the alleged implicit encourage[ment]’ do not,
without more, induce infringement.”217 Further, in Sanofi v.
Watson Labs. Inc.,218 the Federal Circuit inferred the
defendant’s intent to induce infringement from “interpreting the
label’s express statement of indications of use and the internally
referred-to elaboration of those indications.”219
The Supreme Court held in Global-Tech that the scienter
requirement is met if a defendant subjectively believes in a “high
probability” that a patent exists and his actions might lead to
infringement of that patent, yet takes deliberate actions to avoid
learning it.220 The Global-Tech Court, however, rejected using
deliberate indifference to a known risk that a patent exists as
the appropriate standard for finding knowledge or intent, and
articulated that meeting the criminal law standard for willful
blindness is sufficient to satisfy the scienter requirement.221
Additionally, the Commil Court held that while a sincere belief
of noninfringement provides a valid defense to induced
infringement, a sincere belief of patent invalidity alone does
not.222
Lastly, while § 271(c) contains a “substantial noninfringing
use” restriction,223 § 271(b) does not.224 Therefore, the fact that

215. 845 F.3d 1357 (Fed. Cir. 2017).
216. Id. at 1368–69 (citing AstraZeneca, 633 F.3d at 1059–60).
217. Id. (citing Takeda Pharms. U.S.A., Inc. v. West-Ward Pharm. Corp., 785
F.3d 625, 632, 634 (Fed. Cir. 2015)).
218. 875 F.3d 636 (Fed. Cir. 2017).
219. Id. at 645–47.
220. Glob.-Tech Appliances, Inc. v. SEB S.A., 563 U.S. 754, 769 (2011).
221. Id. at 766–68.
222. If the defendant believes that its actions will induce others to literally
infringe the claims, he sincerely believes that its acts will lead to infringement.
It does not matter that he also believes the patent is invalid. Id.; see also Commil
USA, LLC v. Cisco Sys., 135 S. Ct. 1920 (2015).
223. See discussion infra Part II.B.1. on the “substantial noninfringing use”
restriction of § 271(c).
224. See 35 U.S.C. § 271(b)–(c) (commonly known as the indirect
infringement provisions).
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the accused product has other substantial noninfringing uses,
indicated in the instruction or label or not, does not defeat
inducement once the required knowledge/intent is found.225
3. The General Purpose Characteristic of Robotic Surgery
System Companies May Negate the Knowledge/Intent to
Induce or Contribute to Infringement of Others During Medical
Procedures
The analysis in Part II.A.1. and 2. above demonstrates that
a court’s finding of induced or contributory patent infringement,
especially its finding of the knowledge/intent element, relies
heavily on the surrounding facts in a case. Even a slight
deviation in factual finding could lead to different results. For
example, while a product instruction or label that merely
describes the infringing mode alone does not induce
infringement under the current law, a product instruction or
label that uses infringing language to describe the infringing
mode likely induces infringement.226 A specialized robotic
surgery system has specific, evident, and limited uses.227 A
general purpose robotic surgery system, on the other hand, is
expected to have more generic and versatile uses.228 Facts
surrounding specialized and general purpose robotic surgery
systems are different. This difference opens up the possibility of
new defenses against indirect infringement for developers,
manufactures, and sellers of robotic surgery systems. The
versatility of general purpose robotic surgery systems may
defeat the knowledge/intent requirement by §§ 271(b) and (c)
through one or more of the following ways.
First, general purpose robotic surgery systems will likely
implement structures and technology that are more complex
than those implemented by specialized robotic surgery systems.
225. See Sanofi v. Watson Labs. Inc., 875 F.3d 636, 646 (Fed. Cir. 2017)
(reasoning that there can be liability for inducing an infringing use of a drug
though the label contains other substantial noninfringing uses).
226. Compare Takeda Pharms. U.S.A., Inc. v. West-Ward Pharm. Corp., 785
F.3d 625, 630–32 (Fed. Cir. 2015) (holding that a drug label indicating that a
specific infringing use had not been studied was not enough to induce
infringement), with AstraZeneca LP v. Apotex, Inc., 623 F. Supp. 2d 579 (D.N.J.
2009) (holding that when language explaining an infringing use is on the label,
it may induce some consumers to partake in that infringing use).
227. For example, Intuitive Surgical’s newest da Vinci SP currently is
mainly cleared for urology surgeries. See supra Part I.A.
228. Id.
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The evolution of Intuitive Surgical’s da Vinci surgical systems
illustrates this point––the types and sizes of available wristed
instruments expanded229 and the newer da Vinci versions
include even more consoles.230 More complex system structures
and technology means more surrounding facts that may be
investigated and analyzed in patent infringement litigation. It
increases the cost for potential plaintiffs who may wish to pursue
litigation against robotic surgery system suppliers. Litigants
who do not have strong enough claims are thus more likely
deterred by that larger expense.
Secondly, as a robotic surgery system becomes more
versatile, it may be possible for its supplier to provide product
instruction and training at a more general level. For example,
for steps commonly or similarly required by a group of different
procedures, it may be possible to provide more generalized
instructions instead of associating specific procedures with the
steps. Under the current law, relatively general instruction and
training materials are unlikely to demonstrate specific intent to
induce infringement by others.231 In this way, the general
purpose characteristic of a robotic surgery system likely reduces
the risks of secondary liabilities arising out of others’ use.232
Thirdly, the versatility of a robotic surgery system provides
companies with more advertising options. Suppliers of such
systems will arguably have more space to choose, for example, to
selectively demonstrate more general-level features and
functions of the product in which it feels most confident and to
avoid risky, overly-specific descriptions in promotions and
advertisement. Selective advertising does not violate the
FFDCA.233 It may not be possible to draft a generalized label,
since the FFDCA general labeling requirement demands a
robotic surgery system supplier disclose all intended uses for the
device, including any actual uses of which the supplier
reasonably knows.234 However, the FFDCA does not impose such
requirements on advertising, or on all labeling, though it does
make misbranding and poor label control violations the letter of
229. Hagen & Curet, supra note 27, at 11.
230. Id.
231. See supra Part II.A.2 (describing the specific intent requirement).
232. Id.
233. See 21 C.F.R. § 801.5 (outlining the requirements for adequate
directions of use in device labeling).
234. See supra Part I.B.2 (discussing existing labeling requirements).

2022] MAKING ROBOTIC SURGERY GENERAL PURPOSE 629

the law.235 This practice thus also likely reduces the possibility
of improper advertising, which may be used to prove the
knowledge/intent element for indirect infringement.236
B. GENERAL PURPOSE ROBOTIC SURGERY SYSTEMS PROVIDES A
POSSIBLE “SUBSTANTIAL NONINFRINGING USE” DEFENSE TO
CONTRIBUTORY INFRINGEMENT ARISING UNDER § 271(C) FOR
THE SUPPLIERS
As mentioned in Part II.A.2. above, different from § 271(b),
§ 271(c) contains a “substantial noninfringing use” restriction.237
The plain language of § 271(c) exempts any material or
apparatus that is “a staple article or commodity of commerce
suitable for substantial noninfringing use.”238 As established in
yet another copyright law case that borrowed patent law
principles governing contributory infringement, Sony Corp. of
America v. Universal City Studios, Inc.,239 “[u]nless a commodity
‘has no use except through practice of the patented method,’ the
patentee has no right to claim that its distribution constitutes
contributory infringement.”240 In Koninklijke Philips N.V. v. Zoll
Med. Corp.,241 the Federal Circuit articulated an important
requirement for finding substantial noninfringing use of an
accused product: The infringing component must not be
“separate and distinct” from other functions of the composite
product, in order to ensure that a contributory infringer does not
escape liability “merely by embedding the infringing apparatus
in a larger product with some additional, separable feature
before importing and selling it.”242
Accordingly, one possible defense for general purpose
robotic surgery systems suppliers against contributory
infringement under § 271(c) is arguing that the systems have
235. See id.; see also DIV. OF SMALL MFRS. ASSISTANCE OFF. OF TRAINING &
ASSISTANCE, supra note 77, at 37 (“[I]nadequate labeling, or labeling that is less
than it can or should be, may not always violate the law . . . .”).
236. Id.
237. See supra Part II.
238. 35 U.S.C. § 271(c).
239. 464 U.S. 417 (1984).
240. Id. at 441 (citing Dawson Chemical Co. v. Rohm & Hass Co., 448 U.S.
176, 198–99 (1980)).
241. 656 Fed. Appx. 504 (Fed. Cir. 2016).
242. Id. at 524–25 (citing Lucent Techs., Inc. v. Gateway, Inc., 580 F.3d
1301, 1320 (Fed. Cir. 2009) and Fujitsu Ltd. v. Netgear Inc., 620 F.3d 1321,
1330 (Fed. Cir. 2010)).
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other substantial noninfringing uses. Ideally, a general purpose
robotic surgery system should utilize the same set of physical
components to perform a variety of surgical procedures under
the surgeon’s control. Because the accused component would be
the system as a whole, which is not “separate and distinct,” when
one mode of the system is accused of contributing to infringing
use by a medical practitioner, the availability of other system
modes thus may offer a valid “substantial noninfringing use”
defense to the system supplier.
CONCLUSION
In conclusion, the general purpose characteristic of a robotic
surgery system may provide an alternative defense strategy for
its manufacturers and sellers against indirect infringement
liabilities arising out of medical procedure performances using
the system. Specifically, the system’s versatility may help
negate the knowledge/intent element required by both 35 U.S.C.
§§ 271(b) and (c). The increased complexity of the system
generates more surrounding facts. It therefore may be possible
to use higher-level product descriptions and instructions, as well
as selective advertising strategies, to avoid identifying
particular modes of operation which run the risk of showing
infringing intent and knowledge. Further, the same system
versatility demonstrates that substantial noninfringing uses of
the system necessarily exist, yielding a “substantial
noninfringing use” defense to contributory infringement under §
271(c).
Utilizing the general purpose characteristic of a robotic
surgery system as a legal defense is advantageous. It is costefficient and aligns with the trend in robotic surgery technology
of developing more general purpose systems capable of various
uses, and thus best captures the companies’ commercial
interests. The defense, if valid, is relatively strong and could
substantially deter frivolous lawsuits and patent infringement
harassment.

